Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Require RMP Submissions around August for Generics of Blue Letter-Issued Original Drugs
July 2, 2014
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
- JPMA Official Calls for Partial Introduction of CDISC-Based Electronic Applications; Runup Period too Short
June 30, 2014
- Benefits of Electronic Applications to Be Shared by Patients, Companies, and Regulatory Authorities: MHLW Exec
June 30, 2014
- PAFSC’s Second Committee Supports Approval of IFN-Free Hepatitis C Treatments
June 30, 2014
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…